Proteomics of ovarian cancer: functional insights and clinical applications.
Proteomics of ovarian cancer: functional insights and clinical applications.
复制标题
DOI：
10.1007/s10555-014-9547-8
复制
发表时间：
2015-03
期刊：
影响因子：
--
通讯作者：
Rodland KD
中科院分区：
文献类型：
--
作者：
Elzek MA;Rodland KD
在过去的十年里，应用蛋白质组学来帮助了解卵巢癌的发病机制、阐明耐药机制以及开发早期发现卵巢癌的生物标志物的兴趣越来越大。虽然卵巢癌是一系列不同的疾病，但手术和辅助治疗的诊断和治疗策略在不同类型的卵巢癌中是相似的，增加了通过蛋白质组学研究所取得的发现的普遍适用性。虽然蛋白质组学实验面临许多困难，减缓了临床应用的步伐，但蛋白质组学技术的最新进展有助于识别异常蛋白质和网络，这些蛋白质和网络可以作为生物标记物开发和个体化治疗的靶点。本文综述了蛋白质组学对卵巢癌研究的贡献，并重点介绍了目前存在的问题、未来的发展方向和面临的挑战。我们认为，卵巢癌原发灶的蛋白质水平特征可以破解这种疾病的谜团，改进诊断工具，并导致更有效的筛查程序。
In the past decade, there has been an increasing interest in applying proteomics to assist in understanding the pathogenesis of ovarian cancer, elucidating the mechanism of drug resistance, and in the development of biomarkers for early detection of ovarian cancer. Although ovarian cancer is a spectrum of different diseases, the strategies for diagnosis and treatment with surgery and adjuvant therapy are similar across ovarian cancer types, increasing the general applicability of discoveries made through proteomics research. While proteomic experiments face many difficulties which slow the pace of clinical applications, recent advances in proteomic technology contribute significantly to the identification of aberrant proteins and networks which can serve as targets for biomarker development and individualized therapies. This review provides a summary of the literature on proteomics’ contributions to ovarian cancer research and highlights the current issues, future directions, and challenges. We propose that protein-level characterization of primary lesion in ovarian cancer can decipher the mystery of this disease, improve diagnostic tools, and lead to more effective screening programs.